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Abstract | The microbiota is vital for immune system development and homeostasis. Changes 
to its composition and function, termed dysbiosis, in the respiratory tract and the gut have 
recently been linked to alterations in immune responses and to disease development in the 
lung. Here we review the microbial species normally found in the healthy gastrointestinal and 
respiratory tracts, their dysbiosis in disease and interactions with the gut-lung axis. Although 
this gut-lung axis is only beginning to be understood, emerging evidence indicates the 
potential for manipulation of the gut microbiota in the treatment of lung diseases.  
 
 
Chronic lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD) 
are common and often occur together with chronic gastrointestinal tract (GIT) diseases, such 
as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS)1,2. Up to 50% of 
adults with IBD and 33% of patients with IBS have pulmonary involvement such as 
inflammation or impaired lung function, although many patients have no history of acute or 
chronic respiratory disease3,4. Furthermore, COPD patients are 2-3 time more likely to be 
diagnosed with IBD4. Asthmatics have functional and structural alterations of the intestinal 
mucosa and COPD patients typically have increased intestinal permeability2,5. Although the 
mature GIT and respiratory tract have different environments and functions, they have the 
same embryonic origin and consequently have structural similarities. Thus, it is not 
unsurprising that the two sites might interact in health and disease (FIG. 1), but the 
underlying mechanisms are not well understood. 
An emerging area of intense current interest is the influence of the microbiota (defined 
here as a microbial community occupying a defined area of activity6) on local and systemic 
host immunity. This is exemplified by germ-free mice, which lack a properly developed 
immune system and show mucosal alterations, both of which can be restored through 
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colonisation with gut microbiota7,8. The microbiome changes over time from birth, to 
adulthood and into old age, and in response to environmental factors, such as diet, and drug 
and environmental exposures9.  
In this ever-expanding field, researchers are now investigating how the local microbiota 
influence immunity at distal sites, in particular how the gut microbiota influence other organs 
such as the brain, liver or lung. This has led to the coining of terms such as the ‘gut-brain 
axis’ and ‘gut-lung axis’. For example, antibiotic-induced alterations of the gut microbiota in 
early life increases the risk of developing allergic airway disease10-13, which adds to our 
understanding of the links between exposure to microorganisms and allergy and 
autoimmunity (Box 1). The mechanisms by which the gut microbiota affect the immune 
responses in the lung, and vice versa, are being uncovered, but many questions remain. Here, 
we summarise the emerging role of the microbiota in the gut-lung axis, highlighting gaps in 
our knowledge and the potential for therapeutic intervention.  
 
[H1] Microbiomes of the healthy gut and lung 
The GIT remains by far the best-studied host-microbial ecosystem, partly due to its 
abundance of microorganisms and partly because the microbiota can be profiled through 
easily obtainable faeces. Both the abundance and diversity of the commensal microbiota 
generally increase along the GIT, and there are site-specific variations in the mucosa and the 
lumen14,15. These differences are governed by the prevailing environment, including pH, bile 
acid concentrations, digesta retention time, mucin properties and host defence factors16. 
Despite these variations, the GIT microbiome is dominated by four bacterial phyla, 
Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria; with lesser and sporadic 
representation of others including Fusobacteria, Verrucomicrobia and Spirochaetes. This 
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‘core’ gut microbiome comprises up to 14 bacterial genera and 150 bacterial ‘species’, many 
of which have not yet been cultured17-19.  
We are beginning to understand the lung microbiota through programmes such as the 
lung HIV microbiome project, a multi-centre network examining both HIV-infected and 
uninfected persons with varying histories of lung and/or respiratory disease20. The lung has a 
large surface area with high environmental exposure, and is equipped with effective 
antimicrobial defences. Healthy lungs were long considered sterile, however, the advent of 
culture-independent approaches for microbiome profiling has resulted in the detection of 
microbial DNA within the lungs of healthy subjects20,21. These bacteria likely reached the 
lung from the oral cavity through micro-aspiration, as the taxonomic profiles of the two sites 
resembled each other20,21. Compared to surrounding sites, the lung has a reduced abundance 
of Prevotella-affiliated taxa and an enrichment of Proteobacteria, specifically 
Enterobacteriaceae, Ralstonia, and Haemophilus20, which may result from host immunity 
and environment such as redox state and oxygen availability. The lung microbiota might not 
be resident in healthy individuals, but rather transiently recolonise by micro-aspiration and 
breathing. The lungs have a comparatively low bacterial biomass and remarkably similar 
microbial composition to adjacent sites, yet the lungs are continuously exposed to entering 
microorganisms and their environmental conditions differ vastly from other body sites. These 
observations support the hypothesis that entry and selective elimination of a transient 
microbiota is the major determinant of microbiome composition in the lung, as opposed to 
resident and expanding microorganisms. This does not negate the importance of host-
microbiome interactions in the lungs, as evidenced by correlations between microbiome 
composition and pulmonary inflammation and disease22. Rather, it highlights the delicate 
balance of microbial exposure and elimination; the possibility of dysbiosis at oral sites 
preceding and/or causing dysbiosis in the lung and contributing to disease pathogenesis20, 
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and; the importance in distinguishing whether bacterial DNA detected by culture-independent 
techniques is truly representative of viable bacteria in the lungs23. Technical challenges, such 
as low microbial biomass and bronchoscope contamination, constant seeding from oral and 
GIT sites and mucociliary and immune clearance have hindered the identification of a viable 
and resident, or a transiently recolonising microbiome in the lungs, as well as further research 
into host-microbiota interactions. Novel methods of sampling tissue with minimal 
contamination24, longitudinal studies to identify temporal changes in microbiota, and the 
increasing use of metagenomic analysis to facilitate the cultivation of fastidious bacterial 
species25 will provide a clearer picture of the role of the respiratory microbiota and allow for 
better design of interventional studies to develop a more complete understanding of host-
microbiota interactions in the lung. 
 
[H1] Interactions between the gut and lung 
[H3] Interactions of microorganisms between the sites 
The epithelial surfaces of the GIT and respiratory tract are exposed to a wide variety of 
microorganisms; ingested microorganisms can access both sites and microbiota from the GIT 
can enter the lung through aspiration. Both the gut and respiratory mucosa provide a physical 
barrier against microbial penetration, and colonisation with normal microbiota creates 
resistance to pathogens, for example through bacteriocins16. Furthermore, a rapidly 
expanding collection of gut commensal bacteria, including segmented filamentous bacteria 
(SFB), Bifidobacteria spp. and members of the colonic Bacteroides genus, induce the 
production of antimicrobial peptides, secretory IgA and pro-inflammatory cytokines. Non-
pathogenic Salmonella strains downregulate inflammatory responses in GIT epithelial cells 
by inhibiting the ubiquitination of I-kappa-B-alpha26, whereas Clostridia spp. also promote 
anti-inflammatory regulatory T-cell (Treg) responses in the colon27. In the respiratory tract, 
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Streptococcus pneumoniae and Haemophilus influenzae synergistically activate host p38 
mitogen-activated protein kinase in a Toll-like receptor (TLR)-independent manner to 
amplify pro-inflammatory responses28. Conversely, non-pathogenic S. pneumoniae and other 
bacteria and their components can suppress allergic airway disease by inducing Tregs29-32. In 
lung transplant recipients, airway microbiota alters immunity in the lung. Firmicutes or 
Proteobacteria-dominated dysbiosis were associated with expression of inflammatory genes 
in pulmonary leukocytes, whereas Bacteroidetes-dominated dysbiosis was linked to a gene 
expression profile characteristic for tissue remodelling33. In both cell culture33 and animal 
models34, the inflammatory response induced by pathogenic species is greater than that 
induced by commensal microorganisms, indicating that the diverse lung microbiota protect 
against pathology by ‘diluting’ the more pro-inflammatory stimuli of pathogens. Although 
transfer of microorganisms from faecal suspensions has been used to determine the role of the 
gut microbiota, such techniques have not yet been used to transfer respiratory microbiota 
between animals, limiting our understanding of their roles. 
Several studies show the effects of GIT colonisation with orally administered bacteria on 
lung function. Oral gavage of faecal suspensions in mice treated with broad-spectrum 
antibiotics improved survival rate and reduced lung damage induced by S. pneumoniae 
infection35. Even though the nature of this ‘gut-lung axis’ has been challenged due to 
potential confounding effects of faecal administration by oral gavage and antibiotic use36, the 
concept warrants systematic and controlled evaluation. In infants, gut microbiota composition 
and caesarean section have been linked to atopic manifestations, and colonisation by 
Clostridium difficile at age 1 month was associated with wheeze and eczema throughout early 
life, and with asthma at 6-7 years37. Positive associations between the presence of ‘beneficial’ 
bacteria such as Bifidobacterium longum in the gut and a lower incidence of asthma have also 
been identified38, although larger and longer studies are needed.  
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Considerable evidence suggests that host epithelia and other structural and immune cells 
assimilate information directly from microorganisms and from the concomitant local cytokine 
response to adjust inflammatory responses, and that this shapes immune responses at distal 
sites such as the lung39,40 (FIG. 2). There is less evidence of direct transfer of microorganisms 
between sites, although the translocation of GIT bacteria to the lung has been observed in 
sepsis and acute respiratory distress syndrome where barrier integrity is compromised41. 
Additionally, some environmental factors such as dietary fibre can produce similar changes 
in the GIT and lung microbiota40. Whether this results from diet-driven changes in microbial 
metabolites, changes in innate immune responses, or a combination of both remains to be 
determined. 
 
[H3] Microbial species-specific effects on host immunity 
The crucial role of the microbiota in lung homeostasis and immunity is demonstrated by the 
poor outcomes of germ-free mice exposed to acute infections42 and their susceptibility to 
allergic airway disease43. Current research is assessing the impacts of selected members of the 
commensal gut microbiota on systemic immunity including in the lung, as well as the use of 
probiotics and prebiotics to prevent and treat acute and chronic pulmonary disease (FIG. 3). 
For example, SFB in the gut, when present naturally or introduced by probiotic dosing or co-
housing of mice, stimulated pulmonary Th17 responses and protection from S. pneumoniae 
infection and mortality44. Intriguingly, a respiratory microbiome enriched with oral-related 
taxa, such as Prevotella, Rothia and Veillonella, was associated with Th17-mediated 
immunity in the lungs of healthy humans22, whether these links are correlative or causative 
remain unclear. Exposure of mice to dog-associated house dust altered the caecal 
microbiome, and in particular increased the abundance of Lactobacillus johnsonii and other 
Firmicutes-related lineages such as Peptococcaceae and Lachnospiraceae45. Both dog dust-
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exposed mice and mice inoculated with L. johnsonii had reduced Th2 cytokine responses in 
the airways, which protected against exposure to respiratory syncytial virus and allergens 
such as ovalbumin. Other examples of microbial influences on host immunity include the 
ability of various Bacteroides spp. to expand Treg populations or bias the Th1/Th2 phenotype 
in either direction in a strain-specific manner, or the suppression of host inflammatory 
responses by the common bacterial metabolites short-chain fatty acids (SCFAs), which act 
through free fatty acid (FFA) receptors and/or epigenetic regulation of immune cells46.  
In related human studies, seropositivity to the gut-specific pathogen Helicobacter 
pylori, and in particular cagA+ strains, has long been linked with reduced incidence of asthma 
and allergy47,48,49. Conversely, two recent meta-analyses suggest that H. pylori infection is 
positively associated with increased incidence of COPD and other chronic bronchial 
diseases50. Although these differences might be partly attributable to genetic, environmental 
and lifestyle factors, these findings raise the possibility that systemic immune responses 
triggered by H. pylori might have different roles in the aetiology of different lung disorders. 
Strain variations, in addition to the cagA expression, might also affect Treg responses51. 
Clearly, the incredible diversity and abundance of gut microbiota results in many 
immunomodulatory signals, which have considerable combined effects on host health. 
Although much has been uncovered about the activity of specific bacterial species, current 
research has only just begun to assess the structure-function relationships of the gut and lung 
microbiota with host immunity.  
 
[H3] Components and metabolites of gut microbiota that influence the lung 
Early studies showed that germ-free mice have reduced responsiveness to LPS-induced 
pathology and that this oral tolerance to microbial components was due to IL-10 mediated 
hypo-responsiveness; however, subsequent LPS exposure was no longer tolerated and the 
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immune response became similar to that seen in conventional mice52,53. Furthermore, a robust 
response to LPS by colonic macrophages could be restored by commensal microbiota54.  
Bacterial components can also have anti-inflammatory effects, attenuating GIT 
pathology. Polysaccharide A (PSA) from B. fragilis induces IL-10 expression by T-cells and 
protects against intestinal inflammatory disease caused either chemically or by Helicobacter 
hepaticus infection55. Sphingolipids, naturally occurring cell membrane components of many 
gut anaerobic genera including Bacteroides, reduce the number of invariant natural killer T 
cells in the colon, cells which have been implicated in the development of colitis56. The best-
studied metabolites, SCFAs, are by-products of microbial fermentation of dietary fibre, have 
anti-inflammatory properties, are a source of energy for colonocytes, and regulate fatty acid 
and lipid synthesis in the host57. 
Much less is known about the influence of microbial components and metabolites on 
other sites, including the lung. Reductions  in Faecalibacterium, Lachnospira, Veillonella, 
and Rothia in the gut, and the urine levels of some microbial bile acid metabolites correlate 
with the development of atopic wheeze in children, although whether they are a cause or a 
consequence of wheeze is not known13. Oral administration of SCFAs has been shown 
experimentally to alleviate allergic airway disease40,58. Microbial components and metabolites 
have been implicated in other disorders, such as tryptophan in brain health, PSA in the central 
nervous system and trimethylamine N-oxide in atherosclerosis, further highlighting their 
importance in extra-intestinal environments56. In studies of other diseases Bacteroidetes spp. 
were associated with early-onset autoimmune diseases, which may be a consequence of 
potent activation of immunity by the LPS of these bacteria59. 
 
[H1] The gut microbiota and lung diseases 
[H3] Microbiota and asthma 
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An increased risk of asthma has been connected with the disruption of the gut microbiota in 
early life (Box 1), and several studies have sought to characterise the precise microbial 
constituents associated with the development of the disease in infants. 
The overall community composition of the gut microbiome is not altered in infants at 
risk of asthma development, but subtle, transient changes in select taxa can be detected in the 
first few months of life13,60. Increased asthma risk has been associated with increased 
abundance of B. fragilis and total anaerobes in early life61, as well as reduced microbial 
diversity60, Escherichia coli62, Faecalibacterium, Lachnospira, Rothia and Veillonella 
species13, although these findings were not consistent across all studies. Additionally, 
although models of allergic airway disease support the existence of a critical developmental 
window early in life43,63, only one study has provided direct evidence that restoring the 
altered gut microbiome through probiotic treatment can reduce asthma susceptibility13. 
Similarly, in adults, the overall composition of the faecal microbiome in allergic asthma 
does not differ from healthy controls64,65. There are taxa-specific differences, such as 
enrichment of Bifidobacterium adolescentis, which negatively correlated with the time since 
asthma diagnosis64. Interestingly, heat-inactivated Bifidobacterium spp. isolated from allergic 
infants induced greater pro-inflammatory responses than those from healthy individuals66.  
There are several proposed mechanisms through which the microbiota can attenuate the 
risk of asthma development. Infants at risk of developing asthma had reduced levels of LPS 
in their faeces13, whereas PSA from B. fragilis protected against the development of allergic 
airways disease in mice by inducing IL-10 responses in T-cells67. H. pylori alleviated murine 
allergic airway disease in several ways, namely by direct activation of Tregs by neutrophil-
activating protein68, or indirectly through urease B subunit, which promotes tolerogenic 
reprogramming of dendritic cells69. Additionally, γ-glutamyl transpeptidase and vacuolating 
cytotoxin from H. pylori altered dendritic cell function, but did not require Tregs to alleviate 
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symptoms70. Commensal bacteria can also influence asthma development through the 
production and secretion of metabolites, specifically SCFAs. Asthma risk in infants was 
associated with reduced acetate concentration in faeces13 and inversely correlated with serum 
acetate concentrations in their mothers when they were pregnant58. A high-fibre diet, which 
increased levels of SCFAs in serum and faeces, protected mice against the development of 
asthma symptoms, a phenomenon which could be replicated by direct administration of 
acetate or propionate prior to disease onset to promote tolerogenic immune responses in 
dendritic cells and Tregs40,58. The benefits of a high-fibre diet were associated with a reduced 
ratio of Firmicutes:Bacteroidetes and an enrichment of Bacteroidaceae in both the faeces and 
lung, which highlights the necessity of investigating microbial communities at several body 
sites for a complete understanding of the influence of microorganisms on host health. These 
studies did not directly explore the relationship between microbiome composition at the two 
sites, or the relative importance of the gut or lung microbiota in protection against disease. 
Such studies would be valuable in determining which body site to target with therapeutic 
interventions. An important but understudied area is the role of interactions between 
microorganisms in the development of asthma. For example, the loss of intestinal bacteria 
and outgrowth of commensal fungi triggered prostaglandin E2-induced changes in alveolar 
macrophages and increased allergic airway inflammation71. Furthermore, gut helminth 
infection protected mice against allergic airway disease, which was associated with an 
increased abundance of Lachnospiraceae and other Clostridiales members, the production of 
SCFAs and subsequent robust Treg responses in the lungs72. Although the Treg-promoting 
capability of Clostridia spp. have previously been demonstrated in the colon27,73, it is 





[H3] Microbiota and COPD 
Respiratory microbiome research in COPD has assessed changes in the disease state, and 
with smoke exposure, a major risk factor for the development of this disease. Interestingly, 
although the lung microbiome is similar in healthy smokers and non-smokers, the oral 
microbiome differs substantially between the two groups20. As enrichment of lung microbiota 
with taxa from the oral cavity is associated with increased inflammation in smokers76, it is 
plausible that changes in the oral microbiota and a failure to effectively clear aspirated 
microorganisms contribute to disease development, and may help explain why only a subset 
of smokers develop COPD. In any case, there are stark differences in the lung microbiome of 
COPD patients compared to ‘healthy’ smokers77,78, which led to the proposal that the 
respiratory microbiome may be useful in the early diagnosis of COPD. In contrast, no study 
to date has investigated changes of the gut microbiome in COPD patients. Nevertheless, in 
‘healthy’ smokers, the faecal microbiome is characterised by an increase in abundance of 
Bacteroides-Prevotella spp.,79 and a reduced Firmicutes:Bacteroidetes ratio80 compared to 
non-smokers. These changes in microbiota composition have been associated with intestinal 
inflammation and IBD81,82. Smokers also have a reduced abundance of Bifidobacterium80,83, 
and hence may lose the anti-inflammatory effects often associated with this genus.  
The causes of smoking-associated changes in microbiome composition are likely a 
combination of environmental, host and microbial changes such as intestinal and immune 
disruption, impaired clearance of pathogens84,85, acidification of gastric contents86 and 
ingestion of bacteria that occur in cigarettes87. Furthermore, cigarette smoke can directly 
affect the virulence of both bacteria88 and fungi89, as well as altering the growth and 
exopolysaccharide structure of known gut bacteria such as Bifidobacterium animalis90, which 
may contribute to dysbiosis. Even following smoking cessation, many of these changes that 
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cause dysbiosis persist for prolonged periods, and thus any therapeutic intervention to restore 
the microbiota may potentially require repeated administration to avoid relapse. 
In the absence of longitudinal or interventional studies, it is difficult to ascertain whether 
changes in the gut or respiratory microbiome are a cause, or a consequence of COPD. Most 
likely, both are true and operate simultaneously or at different stages of disease. Exposure to 
environmental stimuli and onset of disease cause dysbiosis, which in turn likely contributes to 
disease progression. In any case, defined probiotic use may benefit COPD patients, 
particularly if used as an early, preventative intervention. Oral Lactobacillus casei 
administration improved the previously defective function of peripheral natural killer cells in 
adult male smokers91, whereas Bifidobacterium breve and Lactobacillus rhamnosus reduced 
lung pathology in a mouse model of COPD92, and reduced inflammatory responses in 
macrophages exposed to cigarette smoke extract in vitro93. Similarly, a diet which increased 
SCFA production protected against elastase-induced inflammation and emphysema94. 
Although a causal relationship between SCFAs and protection in this study was not 
confirmed, both cigarette smoke95 and environmental particulate matter96 reduced SCFA 
concentrations in rodents, and cigarette smoke condensate reduced their production in vitro90. 
Furthermore, increased intestinal translocation of bacteria and their products occurred after 
exposure to particulate matter or development of COPD2,96,97. Bacterial toxins such as 
enterotoxin98 or LPS99 can contribute to the pathogenesis of COPD and microbiota-associated 
intestinal inflammation may become systemic and also contribute. The potential of SCFAs to 
improve intestinal barrier function may account for their benefits in animal models of 
COPD100,101, although this is yet to be explored in clinical studies.  
 
[H3] Microbiota and respiratory infections 
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The gut microbiota is broadly protective against respiratory infection, as its depletion or 
absence in mice led to impaired immune responses and worsened outcomes following 
bacterial or viral respiratory infection35,42,102-104. Administration of SFB improved resistance 
to S. aureus pneumonia44 and Bifidobacterium spp. protected against both bacterial105 and 
viral pulmonary infection in mice104,106. Lactobacillus and Bifidobacterium-based probiotics 
also improved the incidence and outcomes of respiratory infections in humans107-110. 
Several aspects of experimental design influence the results of infection studies, 
including the route of administration of bacterial ligands103,111, the facility from which 
research animals are sourced44, the type of antibiotic used for microbiota depletion63,103 and 
the infecting pathogen. For example, herpes simplex virus type 2 or Legionella pneumophilia 
do not appear to be influenced by antibiotic-mediated microbiota depletion103.  
Nevertheless, several important mechanisms by which the gut microbiota promotes 
clearance of infection have been identified. Innate immune responses to bacteria in the lungs 
are greatly enhanced by exposure to NOD-like receptor and TLR agonists in the GIT, 
including peptidoglycan, LPS, lipoteichoic acid and CpG DNA42,102,111. Similarly, stimulation 
of TLRs by gut bacteria cell wall components and flagellin is necessary for effective adaptive 
immune responses to influenza103,112, whereas the anti-inflammatory effects of oral SCFA 
administration are linked to reduced pulmonary pathology following both bacterial105,113 and 
viral114 infection in mice. However, microbiota can also drive gut pathology in pulmonary 
infection. Influenza virus infection in mice increased the number of lung-derived 
CCR9+CD4+ T-cells, which preferentially migrate to the GIT under the guidance of CCL25 
expressed on intestinal epithelial cells115. This resulted in the outgrowth of E. coli and the 
induction of aberrant Th17 responses and intestinal damage. 
 
[H3] Conclusions and perspectives 
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Many studies have identified the presence of a lung microbiome in health and disease. 
However, we believe that the healthy lung microbiota may be transient and best described as 
a progression of taxa influenced by adjacent body sites and the external environment, rather 
than an actively reproducing core resident community. This is not down-playing the 
importance of a transient microbiome in the healthy lung which could still have important 
roles in inflammatory responses whether viable or not. By contrast, the microbiota is more 
likely to be persistent and resident in the airways and lungs in respiratory disease, although 
whether it is a cause or consequence remain to be elucidated. Furthermore, the lung 
microbiota could affect or be affected by microbiota or immune responses at distal sites.  
 The crosstalk between microorganisms and the host is complex and our current understanding 
of these interactions is only in its infancy. It is unlikely that any one of these interactions is 
solely responsible for the functions of the microbiota, and alterations of any part of these 
relationships may be enough to affect health and disease. It is unclear whether changes in the 
microbiota at one site affect many distal sites equally, or if these systemic effects might be 
specific to certain tissues. To date, no such broad study investigating these systemic 
widespread effects has been performed. 
Gut-lung microbiota studies thus far have two major limitations: the first is discerning 
causative over correlative effects, the second is timing. Most studies have been associative. 
Furthermore, culture-independent identification of microbiota has not yet replaced the need to 
isolate and culture suspected opportunistic pathogens or probiotics in order to study their 
effects, and many members of the microbiota cannot be easily cultured. Thus, it is typically 
unclear whether changes observed in the microbiota are the cause or effect of disease. As for 
timing, most experimental data have described the role of the gut microbiota on the 
development of lung disease, and not in established lung disease. Longitudinal studies in 
humans and animals that associate changes in the microbiota with the severity of established 
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chronic lung disease are required. Research into manipulations of the microbiota during lung 
disease is necessary to improve our understanding and inform the development of novel 
therapies (Box 2).  
 Increasingly, microbiome research is moving towards defining the ‘functional’ 
microbiome. As taxonomic variation between sites and individuals is so large, and the 
microbiome consists of thousands of species, it is highly likely that there is redundancy 
between species in terms of their interactions with other microorganisms and in the 
metabolites they produce. Thus, next-generation ‘-omics’ approaches are required to define 
how the microbiomes of the gut and lung interact with each other and influence health and 
disease. 
In summary, lung microbiota in the healthy state may be transient and constantly re-
seeded from the environment and cleared by the immune system, but may still influence 
health and disease. In respiratory diseases the lung microbiota likely becomes persistent and 
may be both a cause and consequence of the disease forming a pathogenic feedback loop. It is 
clear that bacterial components and metabolites in the gut and lung have the capacity to 
modulate systemic and local immunity, with specific taxa able to influence the pathogenesis 
of respiratory diseases such as asthma, COPD and respiratory infections. Such relationships 
have been identified in other respiratory diseases, such as cystic fibrosis116, which, as a 
genetic disease, is a special case. Respiratory challenges with environmental factors such as 
pollution, cigarette smoke, antibiotics, and diet influence disease risk and likely drive 
pathogenesis through their ability to modulate microbiota composition, although the 
mechanisms of these effect remains unknown. Further longitudinal studies and improved 
interventional experiments will help to elucidate the role of the microbiota and gut-lung 
crosstalk in respiratory disease, and will potentially lead to the identification of new and 
effective avenues for treatment.  
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Box 1: The hygiene hypothesis and microbiota 
In 1989, after observing an inverse correlation between the occurrence of hay fever and 
number of siblings, David Strachan coined the term ‘hygiene hypothesis’117. He proposed that 
reductions in the incidence of infections during childhood altered the development of the 
immune system, leading to increased risk of allergic disease. Subsequent studies showed that 
growing up on a farm118, attendance of child care119 and exposure to dog-associated house 
dust45 all protected against the development of asthma. This hypothesis was later modified to 
state that microbial exposure from commensal bacteria that had co-evolved with humans (as 
opposed to faster evolving viruses) were necessary to properly mature the immune system120. 
Both hypotheses have since been used to explain the rise of various autoimmune and allergic 
diseases that correlate well with the decrease in infectious diseases in affluent countries. This 
is now supported by substantial epidemiological evidence for asthma, hay fever117, atopic 
dermatitis121, type 1 diabetes mellitus122 and multiple sclerosis123. 
Expansion of the gut microbiota begins immediately after birth and is heavily 
influenced by environmental factors, with species of the phylum Actinobacteria often 
dominant during infancy124,125. In this early window of life, changes in the microbiota may be 
linked with the development of chronic lung disorders arising in later life. The decline in 
exposure to infectious agents and changes in the microbiota has many causes, including 
improved hygiene and sanitation practices, provision of clean water, pasteurisation, and 
vaccination. Antibiotics directly cause dysbiosis and in infants this may increase 
susceptibility to chronic inflammatory diseases in later life126. Furthermore, the modern diet 
that is high in processed foods also affects the gut microbiota and may have a major but 
currently undefined role in these processes. 
In addition, in areas where helminth infection is rare, the incidence of allergic disease 
is high. Those with chronic helminth colonisation show antigen-specific immune 
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hyporesponsiveness, with increased levels of IL-10 and suppressive Tregs. In addition, 
helminths can influence B-cell differentiation, IgE responses, natural killer T-cell activity and 
macrophage function, to downregulate immune responses and thereby protect the host against 
allergic disease127. 
 
Box 2: Future directions  
Therapeutic efforts that involve the microbiota and are focused on gastrointestinal disorders 
are further advanced than endeavours targeting the gut-lung axis, or indeed targeting the lung 
in general. Whereas initial research has focused on associative studies between 
pathophysiology and microbiota composition, the next step is a shift to causal links, which 
will then indicate interventional strategies for microbiota-modifying or immunomodulatory 
therapeutics. A recent survey of the microbiota intellectual property landscape128 showed that 
patent filings (dominated by food and nutraceutical companies and smaller biotechnology 
start-ups) were directed towards treating infectious diseases (for example, Clostridium 
difficile infection), digestive and metabolic disorders (IBD, type 1 diabetes), and to a lesser 
extent inflammatory and/or immune disorders. Products in development encompass faecal 
transplants and ‘cocktails’ of live microorganisms. In addition, there is interest in microbial 
metabolites and related designer small molecules to beneficially modulate host immune 
responses. For example there are several patents filed on small molecule agonists of FFAR2 
(free fatty acid receptor 2), the host receptor for SCFAs129-131. FFAR2 is a G-protein coupled 
receptor, a class considered to be inherently ‘drugable’, which is expressed on neutrophils, 
eosinophils, and other immune cells and has been linked to exacerbated or unresolved 
inflammation in animal models of colitis, arthritis and asthma132. This provides a link 
between the SCFAs from fermentable dietary fibre and beneficial effects in inflammatory 
diseases such as asthma58. Receptor-targeted approaches such as this may be complementary 
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Figure 1 | Principles of gut-lung crosstalk in health and disease. A healthy intestinal 
microbiota maintains a homeostatic local immune responses through the exposure of 
structural ligands (for example, LPS, peptidoglycan) and secreted metabolites (for example, 
SCFAs). Invading microbiota and absorbed metabolites influence circulating lymphocytes 
and contribute to the regulation of systemic responses. When the gut microbiota is disturbed, 
for example during infection or antibiotic exposure, the normal microbiota-derived signals 
are altered, leading to a transformed immune response. In early life, when the immune system 
is still developing, this disturbance can dramatically alter the way in which the immune 
system perceives its surroundings in later life, leading to chronic inflammatory disorders in 
the gut and lung. In adulthood, dysbiosis of the gut microbiota, for example through exposure 
to cigarette smoke, can cause systemic inflammation and an outgrowth of opportunistic 
pathogens, which can lead to chronic inflammation at distal sites. Although the specific taxa, 
ligands, metabolites and/or host responses may differ in specific disease situations, these 




Figure 2 | Structural and functional similarities and differences between the gut and 
lung. The gut and airway epithelia have substantial differences in functional purpose and 
exist in different environments, yet they retain some anatomical similarities. Both are derived 
from the endoderm and consist of columnar epithelial cells with projections of microvilli 
(gut) or cilia (airway) that function as a physical barrier and as sentinels for the immune 
system in conjunction with associated lymphoid tissue. Both secrete mucus through goblet 
cells as well as secretory IgA (although less in the lung). The alveoli found in terminal 
airways in the lung differ substantially, consisting of squamous epithelial cells that secrete 
surfactant (type 2 alveolar cells) or function in gas exchange (type 1 alveolar cells). The 
similarities end here: the intestinal lumen is an oxygen-poor environment and functions to 
digest food and absorb nutrients. Movement of matter is unidirectional (mouth to anus), with 
the exception of reflux or vomiting. Furthermore, the pH, enzyme presence and structure vary 
along the GIT. In contrast, the airways and alveoli are oxygen-rich, and movement is 
bidirectional (inhalation and exhalation). The gut is of a relatively uniform 37°C, whereas 
airway temperature differs depending on the proximity to the pharynx. Thus, it is 
unsurprising that the microbial life in each environment is distinct. Changes in diet and 
exposure to therapeutics and environmental particulates can directly affect the composition of 
the microbiota. Both the gut and lung are able to influence each other’s immune responses. 
Dendritic cells in the intestine and airways, and macrophages in the lungs, sample antigens in 
the lumen. Lymphocytes in the associated lymphoid tissues circulate through the lymphatic 
system to affect systemic immunity. Bacteria from the gut can travel to the lung through 
aspiration of vomit or oesophageal reflux. In times of dysbiosis, disturbed epithelial integrity 




Figure 3 | Immune system programming by microbiota. Secreted and structural 
components of microbiota can influence the host immune response both locally and at distal 
sites. Microbial metabolites, such as short chain fatty acids (SCFAs), bind free fatty acid 
receptors or promote epigenetic changes in host leukocytes, which induce anti-inflammatory 
responses and reduce inflammation. Virulence factors from pathogenic bacteria, such as 
Helicobacter pylori or Bacteroides fragilis, can downregulate host immune responses, 
whereas structural components from commensal bacteria influence inflammatory responses 
through the activation of pattern recognition receptors. LPS, lipopolysaccharide; LTA, 
lipoteichoic acid; PSA, polysaccharide A; UreB, urease subunit beta; VacA, vacuolating 
cytotoxin A; GGT, gamma-glutamyl transpeptidase; NAP, neutrophil-activating protein. 
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Microbiota: a microbial community occupying a defined area of activity 
 
Key Points 
 The gastrointestinal tract (GIT) and respiratory tract, while separate organs, are part of 
a shared mucosal immune system termed the gut-lung axis. 
 The microbiota of the GIT and the respiratory tract are involved in the gut-lung axis, 
influencing immune responses both locally and at distant sites   
 Current research has identified specific bacterial taxa, their components and 
metabolites which can influence host immunity. 
 With greater knowledge of the gut-lung axis and microbial influences of immunity, 
great advances have been made in understanding the role of microbiota in respiratory 
diseases such as asthma, chronic obstructive pulmonary disease and respiratory 
infection. 
 This newfound understanding has created a number of possible therapeutic strategies 
for the treatment or prevention of acute and chronic respiratory diseases. However, 
several technical challenges and unanswered questions remain. 
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